Exact Sciences Obtains Exclusive License to Oncomethylome Sciences' DNA Methylation Biomarkers
Exact Sciences Corp. and OncoMethylome Sciences S.A. announced that they have entered into a license agreement under which Exact Sciences has obtained exclusive, worldwide rights to up to two OncoMethylome Sciences' DNA methylation biomarkers for use in stool-based detection of colorectal cancer. Exact Sciences has also gained non-exclusive access to part of OncoMethylome's platform technology. In return, OncoMethylome Sciences will receive milestone payments and royalties on net sales.
DNA methylation regulates gene expression, and multiple scientific studies have shown that methylation markers are clinically relevant markers for colorectal cancer. In cancers and pre-cancers, methylation biomarkers are typically present more frequently than individual DNA mutation biomarkers, and as a result, fewer methylation markers are required to detect most cancers and pre-cancers.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.